Loading...
•
Sep 30, 2025
•/
Organigram Q4 2025 Earnings Report
Organigram reported a significant increase in revenue but widened its net loss in Q4 2025.
Key Takeaways
Organigram's Q4 2025 results showed strong revenue growth driven by international sales and acquisitions. However, the company reported a larger net loss due to non-cash fair value adjustments.
Revenue by Geographic Location
Forward Guidance
Organigram expects revenue to exceed $300M in FY2026, driven by expanded demand and operational efficiencies.
Positive Outlook
- Net revenue forecasted to exceed $300M in FY2026
- Expected margin expansion
- Increasing international demand
- Improved cultivation performance
- Streamlined logistics and stronger product mix
Challenges Ahead
- Pending EU-GMP certification outcome
- U.S. regulatory risks from hemp THC legislation
- Higher SG&A expenses due to acquisitions and ERP costs
- Cash burn from working capital investments
- No guidance provided on profitability or EPS
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...